Prefilled Syringes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast (2012 - 2018)

Prefilled syringes are primary injectable drug delivery devices administered by a medical practitioner or a healthcare provider. These syringes are prefilled with drugs with an appropriate and prescribed amount, and so are ready to be used by the patients directly. Currently, there are over 60 types of drug prefilled syringes available in the market and many more are in product pipelines. Rising incidences of chronic diseases requiring regular drug administration and the rising home healthcare market are the two most influential growth drivers for the prefilled syringes market. In an attempt to comply with the U.S. and European needlestick prevention laws, manufacturers are utilizing ancillary devices to ensure device safety. This increases the cost associated with the manufacturing and storage of prefilled syringes and impedes the growth of the market. Glass is a preferred raw material for prefilled syringes manufacturing owing to its strength, chemical inertness, and dimensional stability. Plastic is an alternative raw material used in prefilled syringe manufacturing.

Browse for full report: http://www.transparencymarketresearch.com/prefilled-syringes-market.html

The market is segmented on the basis of product types into single chamber and double chamber syringes. The geographical segmentation of the market constitutes North America, Europe, Asia, and the rest of the world regions. In 2011, the North American market was the largest one in terms of revenue generation, followed by Europe.

Some of the major players of the market include Becton, Dickinson & Company, Gerresheimer, West Pharmaceutical Services, MGlas AG, Nuova Ompi, SCHOTT, and others.  All these companies adopt strict and extensive research and development initiatives to identify growth opportunities and capitalize on them via new and technologically advanced products.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

• North America
• Asia Pacific
• Europe
• Rest of the World

This report provides comprehensive analysis of

• Market growth drivers
• Factors limiting market growth
• Current market trends
• Market structure
• Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth
• It provides a technological growth map over time to understand the industry growth rate
• It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
• It provides distinctive graphics and exemplified SWOT analysis of major market segments.

Read More

Pulmonary Arterial Hypertension Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast (2012 – 2018)

Pulmonary arterial hypertension (PAH), a type of pulmonary hypertension results from high blood pressure associated with arteries of the lungs. In PAH, the arteries of the lungs (pulmonary arteries) become narrower than their actual size, giving rise to high blood pressure in the arteries of the lungs thus putting pressure on the right ventricle of the heart. Some of the main causes of occurrences of this disease are bad habits such as stressful lifestyle, intake of certain medicines etc. There is no exact treatment available for PAH but existing medication may help treat the symptoms. Moreover, if not treated in time the condition may worsen, because continuously straining the pulmonary arteries will put strain on the heart’s functioning and can be life threatening.

Browse full report at: http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

The global PAH market is set to grow at a healthy growth rate due to increasing number of patients identified with PAH, increased competition among existing products, advancement in treatment options and more efficacious therapies.  Some of the major drugs available for the treatment of PAH include Letairis (ambrisentan), Adcirca (tadalafil), Tracleer (bosentan), Ventavis (iloprost), Tyvaso (inhaled treprostinil), Remodulin (treprostinil), Veletri (epoprostenol) and Revatio (sildenafil). Revatio, Remodulin and Letairis/Volibris were some of the leading drugs in some of the major geographies such as the U.S., Spain, U.K., France, Germany, Italy, and Japan.  The PAH market is segmented on the basis of mechanism of action which includes platelet aggregation inhibitors, serotonin pathway antagonists, angiotensin receptor antagonists, endothelin receptor antagonists, PDE5 inhibitors, phosphodiesterase inhibitors, P2Y 12 receptor inhibitors, nitric oxide synthetase inhibitors and prostacyclin (PGI2) agonists.

Some of the key market players profiled in this report include Novartis AG, Bayer AG, Eli Lilly and Company, SanofiAventis, Pfizer Inc., Cipla Limited, GlaxoSmithKline Plc, Daiichi Sankyo Co., Arena Pharmaceuticals, Inc., United Therapeutics Corporation, Gilead Sciences, and Nippon Shinyaku Co., Ltd., among others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

• North America
• Asia Pacific
• Europe
• Rest of the World

This report provides comprehensive analysis of 

• Market growth drivers
• Factors limiting market growth
• Current market trends
• Market structure
• Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth
• It provides a technological growth map over time to understand the industry growth rate
• It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
• It provides distinctive graphics and exemplified SWOT analysis of major market segments.

Read More

Global Insulin Market Expected to Reach USD 32,346.7 Million in 2018, with China Alone Accounting for 10.2%

According to a new market report published by Transparency Market Research "Insulin Market - Global and China Scenario, Trends, Industry Analysis, Size, Share and Forecast, 2011 - 2018" the global insulin market was worth USD 12,476.3 million in 2011 and is expected to reach USD 32,346.7 million in 2018, growing at a CAGR of 12% from 2011 to 2018. In the global market, China is expected to increase its share in the global insulin market to 10.2% by 2018.

Browse the full report at http://www.transparencymarketresearch.com/insulin-market.html 

The global insulin market is driven by rise in diabetic population worldwide. The world diabetes population was estimated at 366 million in the year 2011, and is expected to reach 552 million in 2030. It is estimated that diabetes accounts for 4.6 million deaths, with cases of people dying due to lack of insulin and not even being diagnosed. This however, presents a huge supply demand deficit for insulin, with high growth potential in developing markets. The factors contributing to the insulin market growth also includes increase in global expenditure on healthcare, strong distribution network, and high scope in developing economies such as China and India.

It is estimated that worldwide, by year 2030, one in ten people will suffer from diabetes, giving rise to huge demand for insulin. China, being the most populous nation in the world, accounts for the largest share of the global diabetic population and eventually turns out as the most lucrative market for insulin manufacturers.

The China insulin market is projected to grow at a CAGR twice that of the global insulin market. It was estimated at USD 723.8 million in 2011, and is projected to reach USD 3,299.1 million in the year 2018, growing at a CAGR of 24.6%. Currently, China accounts for 6.1% of the global insulin market in terms of volume, which was estimated at 22.4 tMU in 2011. The global insulin market by volume is projected to grow at a CAGR of 7.9% from 2012 - 2018.

The global insulin market has continuously witnessed new advanced product types being introduced in the market by insulin manufacturers. The recent product type is modern insulin, which is a genetically engineered version of human insulin, and has been selectively modified to counter the issues associated with human insulin. Currently, modern insulin accounts for more than 76% of the global insulin market.

To meet the rising demand, global insulin manufacturers are not only augmenting existing production facilities, but also expanding their global presence to meet the supply demand gap. Leading insulin manufacturers are now focusing on reinforcing their market leadership in China. It includes key global and China insulin market players such as Novo Nordisk, Sanofi-Aventis, and Eli-Lilly. Together they account for more than 90% of the global insulin market share.

This research is specially designed to estimate and analyze the demand and performance of the global and China insulin market in the current market scenario. This research provides in-depth analysis of insulin manufacturers, product sales, trend analysis by segments, and demand by geography. 

The report covers all the major product segments of the global and China insulin market and provides in-depth analysis, historical data and statistically refined forecast for the segments covered. The study presents a comprehensive assessment of the stakeholder strategies and winning imperatives for them by segmenting the global and 

China insulin market as below:

By Action

• Short Acting
• Pre-mixes
• Long Acting

By Type

• Modern
• Human
• Animal

By Purchase Type

• Dosage
• Bulk

Browse  Blog : http://medicalcaremarketnews.wordpress.com/

http://rahul28feb.blogspot.in/

Read More

Neuromodulation Devices Market - Global Industry Size, Market Share, Trends, Analysis, And Forecast 2012 - 2018

According to a new market report published by Transparency Market Research  "Neuromodulation Devices Market - Global Industry Analysis, Size, Share and Forecast, 2012 - 2018," the global neuromodulation devices market was valued at USD 2,758 million in 2011 and is expected to grow at a CAGR of 14.4% from 2012 to 2018, to reach an estimated value of USD 7,072.6 million by 2018.

Browse the full report at http://www.transparencymarketresearch.com/global-neuromodulation-devices-market.html

The market is driven by factors such as the aging world population leading to chronic 

diseases such as Parkinson's and Alzheimer's disorders and technological advancements in the field of neuromodulation devices including the invention of transdermal neuromodulation technology by NMT (Neurowave Medical Technologies). Moreover, the rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, the availability of external funding to conduct clinical studies to help come up with new and technologically advanced products and the rising healthcare related consumer expenditure have also driven the growth in this market. The fact that a neuromodulation device could be used as an add-on treatment and so can be used simultaneously with other medications also drives the market forward.

The North American region holds majority of the market share and accounted for a share of 65% in 2011. The North American neuromodulation device market was valued at USD 1,792.7 million in 2011. The economic developments in the Asia Pacific region make it the fastest growing region (CAGR of more than 15% from 2012 to 2018) in the neuromodulation devices market.

The future growth of the market will be ensured by capitalizing on market opportunities such as increasing healthcare related consumer expenditure in emerging economies in the Asia Pacific, Latin American and Eastern European regions. The availability of medical device manufacturing outsourcing options helps in curbing costs and thereby enhances profit margins. Also, the presence of consolidation options in the healthcare industry helps in strengthening the revenue base to conduct R&D exercises for new product development and thus helps in strengthening market share.

Implementation of the Affordable Healthcare for America Act, 2010 which imposes an excise tax of 2.5% on medical devices and the stringent FDA regulations are some of the factors restraining the growth of the market. Risks involved in using a neuromodulation device such as injury to the vagus nerve and nearby blood vessels (carotid artery and jugular vein) in case of a vagus nerve pacemaker also impedes the growth of the market.

Neuromodulation Devices Market by Technology

• Spinal Cord Stimulation Devices
• Deep Brain Stimulation Devices
• Vagus Nerve Stimulation Devices
• Sacral Nerve Stimulation Devices
• Gastric Electric Stimulation Devices

Neuromodulation Systems for Different Application Areas

• Medtronic's Spinal Cord and Deep Brain Neurostimulation Systems
• St. Jude Medical's Eon  Mini Neurostimulator System
• Boston Scientific's Precision Spinal Cord Stimulation System
• Nevro's Senza System for Spinal Cord Stimulation
• Cyberonics' VNS Therapy System
• Codman & Shurtleff's Medstream system
• Medtronic's Enterra™ Therapy System
• IntraPace's abiliti system

Neuromodulation Devices Market by Geography

• North America
• Europe
• Asia Pacific
• RoW (Rest of the World)

Browse Bolg : 

Medicalcare And Pharmaceutical Market News

 

http://medicalcaremarketnews.wordpress.com

Read More

Chemotherapy Induced Nausea and Vomiting (CINV) Existing and Pipeline Drugs Market is Expected to Reach USD 2.1 Billion Globally in 2018

According to a new market report published by Transparency Market Research "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron FDC, APF530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018," the global CINV market was worth USD 1.3 billion in 2011 and is expected to reach USD 2.1 billion in 2018, growing at a CAGR of 7.1% from 2013 to 2018. The North American CINV existing and pipeline drugs market is expected to reach USD 1.0 billion in 2018. Sluggish economic growth and a poor reimbursement scenario in European countries have hampered the growth of CINV drugs market in these 

regions.

Browse the full report With  TOC at http://www.transparencymarketresearch.com/cinv-market.html

Nausea and vomiting represent the most frequent side-effects experienced by chemotherapy patients, referred to as chemotherapy-induced nausea and vomiting (CINV) Market, which is debilitating to cancer patients. Emetogenic refers to the likelihood of a chemotherapy drug affecting the patient in an adverse manner, leading to added illness or sickness. Highly emetogenic chemotherapy (HEC) mostly leads to nausea and vomiting in 90% or more of the cases, while moderately emetogenic chemotherapy (MEC) causes nausea and vomiting in 30-90% of the cases.

Current drug treatments available to prevent CINV have failed to completely overcome the symptoms of this disease. Moreover, most of the drugs are approved for acute-onset CINV whereas there is no drug approved yet for delayed-onset CINV for patients receiving HEC, which occurs more frequently (50-70% of patients) in the cancer population.

The inefficiency to effectively predict CINV incidence and understand the complex physiology of CINV by healthcare providers coupled with the failure to adhere to recommended guidelines, have been prominent reasons for deficiency in CINV treatment.However, the current pipeline in the CINV market offers huge potential to overcome such unmet needs, with better and efficient drugs for both acute and the more prominent, delayed-onset CINV.

Netu-palo FDC of Helsinn Healthcare, currently in phase III trials, which was in-licensed by the Helsinn group from Roche in the year 2005, helps in preventing CINV in acute as well as delayed-onset CINV patients. Due to its combination of a 5-HT3 antagonist and an NK-1 antagonist, the netu-palo FDC helps in overcoming unmet needs existing with current drug treatments available, which are mostly 5-HT3 antagonists. Moreover, other drugs in the pipeline, namely, APF530 and rolapitant offer physicians alternative treatment options for patients who show little relief from existing drugs in the market.

This research is specially designed to estimate and analyze the demand and performance of the CINV pipeline drugs in a global scenario. The research provides in-depth analysis of CINV pipeline drugs manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major product segments of the global CINV pipeline drugs market and provides detailed analysis, historical data and statistically refined forecast for the segments covered.

The study presents a comprehensive assessment of the stakeholder strategies, winning imperatives for them by segmenting the global CINV pipeline drugs market as below:

• CINV - Pipeline Products APF530 (long-acting granisetron - 5-Ht3RA)
• Efficacy Results of APF530 MEC Phase III Study
• Efficacy Results of APF530 HEC Phase III Study Rolapitant (NK-1-RA)
• Chemical structure of rolapitant
• Netupitant-Palonosetron FDC
• Introduction
• Mechanism of action
• Chemical structure of netupitant
• Unmet Needs in the CINV Market
• Clinical Trial Details for CINV pipeline drugs APF530
• Clinical Trial: ID- NCT00343460 Rolapitant
• Clinical Trial: ID - NCT01500226
• Clinical Trial: ID - NCT01500213
• Clinical Trial: ID - NCT01499849 Netupitant-palonosetron FDC
• Clinical Trial: ID - NCT01376297
• Clinical Trial: ID - NCT01339260

In addition the report provides a cross-sectional analysis of all the above segments with respect to the following geographical markets:

• North America
• Europe

Read More

Bioinformatics Market is Expected to Reach USD 9.1 Billion in 2018

According to a new market report "Bioinformatics Market - Global Industry Size, Market Share, Trends, Analysis and Forecast, 2012 - 2018," published by Transparency Market Research, the global bioinformatics market is estimated to reach market size worth USD 9.1 Billion in 2018. The market is forecasted to record double digit growth, with highest revenue contribution from the bioinformatics platforms segment.

Browse the full report at http://www.transparencymarketresearch.com/bioinformatics-market.html

The global bioinformatics market, estimated at USD 2.3 billion in 2012 is forecasted to reach a market size of USD 9.1 billion in 2018, at a CAGR of 25.4% from 2012 - 2018. The market growth is driven by rise in applications across various industries. The key contribution to the market demand is from fields such as agriculture biotechnology, pharmaceutical research and development, medical and clinical diagnostics, and other life-sciences related industries.

The bioinformatics platform holds the largest market share and is estimated to account for nearly 50% of the market revenue. The services market currently holds a relatively smaller market share, however is expected to increase considerably over the forecast period. The bioinformatics platform segment is the fastest growing market and is expected to contribute 54% of the total market growth during the same period.

The demand across genomics and wide application in the medical and biological information sector is driving the demand for bioinformatics platforms and services in the global market. The research outsourcing by pharmaceutical giants in the fields involving bioinformatics content is a significant driver of the global bioinformatics market. These companies in efforts to reduce time and cost on R&D activities involved in the development of novel drugs and new applications for existing drugs, are looking for outsourcing services for bioinformatics knowledge and management tools, platforms, and services.

Among the regional markets, North America holds the largest share; however, is forecasted to be succeeded by Europe as the leading market share holder in 2018, due to fast growth shown by major European markets such as Germany and U.K. Europe is forecasted to be the fastest growing region, with growth mainly driven by rising government support for R&D activities in the region. The bioinformatics services market in Europe and North America is well developed and organized whereas it is still in initial growth stage in emerging markets of Asia Pacific region.

The report analyzes the global bioinformatics market growth across various segments such as knowledge management tools, platforms, and services. The in-depth analysis includes analysis of sub-segments up to three levels, with cross sectional analysis on the basis of geographical and regional market size and forecasts. The cross-sectional analysis of the global bioinformatics market based on applications further provides market growth potential across various end user industries. The segments considered on the basis of application are - molecular medicine, gene therapy, drug development and preventive medicine.

Browse All Market Research Report : http://www.transparencymarketresearch.com/

Browse Blog : http://medicalcaremarketnews.wordpress.com/

Read More

Global Market For Cloud Computing In Healthcare - 2018

According to a new market report published by Transparency Market Research "Cloud Computing Market In Healthcare Industry (IaaS, SaaS, PaaS, CIS, NCIS, PACS, EMR, RIS) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global cloud computing market in the healthcare industry was valued at USD 1.82 billion in 2011 and is expected to reach USD 6.79 billion by 2018, growing at a CAGR of 21.3% from 

2012 to 2018.

Browse the full report at http://www.transparencymarketresearch.com/healthcare-cloud-computing.html 

The rising costs of delivering healthcare services to the patient community helped the healthcare industry to evolve as one of the largest industries with trillions of dollars spent within the public and private sector. Aging population and global economic development has resulted in demand for better healthcare services, thus driving the growth of the healthcare industry. Cost effective approaches with optimal operational efficiency are in demand. Cloud computing helps healthcare organizations share all the information which is stored across various information systems in real time and increases productivity and cost-efficiency. The cloud computing market in healthcare industry is estimated to witness high growth in the coming years.

Strong growth in this market is attributed to the need for healthcare organizations (HCO) to manage and optimize their complex IT systems, provide faster and flexible healthcare delivery to patients and physicians through mobile and other easy access systems, compliance with regulatory standards and maintain confidentiality regarding patient data. Cloud deployment enables healthcare organizations to reduce expenditure, manages complex healthcare processes, maintains patient information securely and hence is expected to penetrate even more in the healthcare market in the coming years.

The North American region held the majority of market share in 2011 followed by Europe and Asia. Key players dominating this market are CareCloud, ClearDATA Networks, Merge Healthcare, Agfa Healthcare, IBM Corporation, Microsoft, Carestream Health, Oracle Corporation and others.

The study presents a comprehensive assessment of the stakeholder strategies and their winning imperatives by segmenting the healthcare cloud deployment as below:

• Global cloud computing market in healthcare industry by pricing models

• Spot pricing or subscription model
• Pay-as-you-go model
• Global cloud computing market in healthcare industry by service models

• Infrastructure-as-a-Service (IaaS)
• Platform-as-a-Service (PaaS)
• Software-as-a-Service (SaaS)
• Global cloud computing market in healthcare industry by end user applications

• Clinical Information systems (CIS) cloud computing market

• EMR
• PACS
• RIS
• Others
• Non-Clinical Information systems (NCIS) cloud computing market

• RCM
• Claims management
• APB
• Others
• Global cloud computing market in healthcare industry by geography

• North America
• Europe
• Asia
• RoW

Browse All Market Research Report : http://www.transparencymarketresearch.com/

Browse Bolg : Business Research Industry

http://businessresearchindustry.blogspot.com/

http://rahul28febblog.wordpress.com

http://medicalcaremarketnews.wordpress.com

Read More